Pharmaids Pharma (524572)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales grew 15.29% year-on-year, showing some demand traction
• Market cap of ₹170 crore is small, allowing potential for niche pharma opportunities
• Trades above book value but the downside may be limited if losses narrow

Concerns

• Net loss of ₹3 crore on quarterly sales of ₹5 crore—severe operating inefficiency
• ROE of -17.80% and ROCE of -17.43% indicate persistent value destruction
• Piotroski F-Score of 3/9 signals poor financial fundamentals
• Zero dividend and no promoter holding disclosure reduce confidence

AI Analysis

When I look at Pharmaids Pharma, I see a business that fails almost every test I apply. The price is ₹48.11, yet the company earned nothing—the P/E is zero because there are no positive earnings to speak of. The latest quarter tells the story: sales of just ₹5 crore and a net loss of ₹3 crore. Over the year, profit fell by 9.47% even as sales grew 15.29%. That is not a business creating value; it is burning cash while trying to grow. The return on equity is -17.80%, and return on capital employed is -17.43%. As Graham would say, the margin of safety is nowhere to be seen. The book value is ₹17.47, but the market is paying ₹48.11—a P/B of 2.75—for a loss-making enterprise. That premium seems to be based on hope, not arithmetic. The Piotroski F-Score of 3 out of 9 confirms poor financial health. With no dividend, no promoter holding disclosed, and debt-to-equity unknown, I cannot assess the balance sheet properly. In investing, what you don't know is often more dangerous than what you do know. The 52-week range of ₹27.10 to ₹66.00 suggests a volatile, speculative stock. I prefer predictable, profitable businesses run by honest, visible owners. This is a turnaround story at best, but there is no evidence of a successful turnaround. I would be a buyer only at a deep discount to book value, and even then, only after clear proof that losses are reversing. Today, this is a pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer